Proxima Bio GmbH develops AI-based platforms for drug discovery and the analysis of protein interactions. The company focuses on structure prediction, molecular design, and data platforms for proximity-modulation therapeutics.
AI-generated
Offering
Products & services
Industry:Research & DevelopmentPharmaceutical IndustrySoftware Development
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Drug discovery with an integrated model for structure prediction, de novo generation, protein and small-molecule design, docking, inpainting, and lead optimization.
Structural Proteomics and Cross-Linking Mass Spectrometry
Structural data platform based on XLMS for measuring interatomic distances, generating structural restraints, and reconstructing complex protein structures.
Protein Structure Prediction and Molecular Docking
Structure prediction for monomers and complexes, including protein-protein, protein-ligand, and ProMod-bound systems, plus docking-based use of available structures.
Molecular Glue and ProMod Development
Development of molecular glue and proximity-modulation therapeutics, including ternary complexes, PROTACs, and other protein-recruiting therapies.
Comparisons
Proxima Bio GmbH in comparison
Soon
Industry comparisons are coming soon
We're preparing industry comparisons that rank Proxima Bio GmbH by reviews, experience and specialisations.
Knowledge
No knowledge articles yet
Once Proxima Bio GmbH has claimed this profile, we'll publish editorial articles and case studies here together.